Fig. 1

MiR-10a-5p enhances gemcitabine resistance in vitro and vivo. a MiR-10a-5p was significantly up-regulated in AsPC-1-Gem cells (AsPC-1/GR), as determined using quantitative RT–PCR; b transient and stable miR-10a-5p transfection efficiency in the AsPC-1 cell line; c miR-10a-5p mimics significantly increased gemcitabine resistance in AsPC-1 cells; d miR-10a-5p inhibitor significantly decreased gemcitabine resistance in AsPC-1 cells; e miR-10a-5p levels in six PDAC cell lines; f transfection efficiency of miR-10a-5p in T3M4 and Su86.86 cell lines; g miR-10a-5p mimics significantly increased gemcitabine resistance in T3M4 cells; h miR-10a-5p inhibitor significantly decreased gemcitabine resistance in Su86.86 cells; i pictures of tumors from nude mice 4 weeks after the gemcitabine treatment; j tumor growth in nude mice after the gemcitabine injections; k tumors with high miR-10a-5p levels were significantly larger than control tumors 4 weeks after treating with gemcitabine. The data are presented as the means ± SD. (Student’s t-test; *, P < 0.05)